Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) Q1 Earnings and Revenues Miss Estimates
Organon (OGN) came out with quarterly earnings of $0.71 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $1.02 per share a year ago.
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout
OGN stock soars as Sun Pharma strikes $11.75B all-cash deal, aiming to expand biosimilars reach and boost global pharma standing.
Organon (OGN) Soars 30.9%: Is Further Upside Left in the Stock?
Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.
India's Sun Pharmaceutical Industries agrees to buy the women's health company for $14 a share in an all-cash deal.
Why is Sun Pharma betting $11.75B on a struggling US drugmaker?
In one of the biggest outbound acquisitions ever attempted by an Indian company, Sun Pharmaceutical Industries has decided to buy Organon & Co. for $14 a share in an all-cash deal valued at $11.8 billion The logic of the deal is easy to state and harder to execute as Sun is not buying a fast-growing asset, but a scaled global platform with meaningful cash flow, a large commercial footprint and a huge debt load. Sun is planning to expand in women's health, biosimilars and innovative medicines, while Organon brings more than 70 products across women's health and general medicines in 140 countries.
Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal
Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion. Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share.
Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion
Sun Pharma has offered to pay $14.00 a share in an all-cash deal.
Sun Pharma to acquire Organon in $11.75 bln all-cash deal
Sun Pharmaceutical Industries will acquire Organon & Co in an all‑cash deal, valuing the U.S. drugmaker at about $11.75 billion, the companies said in a joint statement on Sunday.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
